Cession Oncology

Biotechnology Research • • 1-10 Employees

Company overview

Headquarters	XX
Website	cessiononcology.com
NAICS	541714
Founded	2025
Employees	1-10

Key Contact at Cession Oncology

David Seaburg

Member Board of Directors

About Cession Oncology

Cession Oncology is a late preclinical-stage biotechnology company advancing cutting-edge therapies to transform the treatment of pancreatic cancer and other deadly cancers. Our proprietary nanoparticle technology, developed at Georgetown University Medical Center, has shown a remarkable ability to inhibit primary tumor growth and completely halt metastasis in pancreatic cancer models. We’ve built a world-class team with deep expertise spanning academia, industry, and investment.

Cession Oncology revenue & valuation

Annual revenue	$171,110
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$547,552
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Funding Data

Cession Oncology has never raised funding before.

Frequently asked questions

Cession Oncology is located in XX.

Cession Oncology was founded in 2025, making it 1 years old. The company has established itself as a significant player in its industry over this time.

Cession Oncology has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Cession Oncology

David Seaburg

Member Board of Directors

4.8

40,000 users